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Abstract
Medication non-adherence is a common precipitant of heart failure (HF) hospitalization and is 
associated with poor outcomes. Recent analyses of national data focus on long-term medication 
adherence. Little is known about adherence of HF patients immediately following hospitalization. 
Hospitalized HF patients were identified from the Atherosclerosis Risk in Communities (ARIC) 
study. ARIC data were linked to Medicare inpatient and Part D claims from 2006–2009. Inclusion 
criteria were: a chart adjudicated diagnosis of acute decompensated or chronic HF; documentation 
of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), beta-
blocker (BB), or diuretic prescription at discharge; Medicare Part D coverage. Proportion 
ambulatory days covered (PADC) was calculated for up to twelve 30-day periods after discharge. 
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Adherence was defined as ≥80% PADC. We identified 402 participants with Medicare Part D: 
mean age 75, 30% male, 41% black. Adherence at 1, 3 and 12 months was 70%, 61%, 53% for 
ACEI/ARB, 76%, 66%, 62% for BB, and 75%, 68%, 59% for diuretic. Adherence to any single 
drug class was positively correlated with being adherent to other classes. Adherence varied by 
geographic site/race for ACEI/ARB and BB but not diuretics. In conclusion, despite having Part D 
coverage, medication adherence post discharge for all three medication classes declined over 2–4 
months after discharge, followed by a plateau over the subsequent year. Interventions should focus 
on early and sustained adherence.
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Most studies of medication adherence in heart failure (HF) patients have focused on long-
term adherence.1–8 Little is known about the temporal trend of medication adherence 
immediately after hospitalization in patients with documented discharge medications.9 
Previous studies often required a filled prescription for study inclusion, which may 
overestimate adherence.2–7, 9 In the few studies that have utilized Medicare Part D data, 
adherence has been described in patients with either an inpatient or outpatient HF 
claim.4, 5, 7 However, no study using Medicare Part D data has examined adherence to HF-
specific medications immediately after hospitalization. This issue is of significant policy 
interest since the Centers for Medicare and Medicaid Services (CMS) is now tying payment 
to readmission rates for some chronic diseases, including HF. These initiatives have led to 
increased emphasis on interventions to reduce readmissions.10, 11 Prior work has 
demonstrated improved rates of guideline-concordant medication prescribed at discharge, 
but we know relatively little about adherence and its determinants post-discharge. To 
determine whether medication adherence changes over time, we examined monthly 
medication adherence for angiotensin converting enzyme inhibitor/angiotensin receptor 
blocker (ACEI/ARB), beta-blocker (BB), and diuretic therapies for up to 1 year after 
hospitalization using Part D data available for participants of the Atherosclerosis Risk in the 
Communities (ARIC) study. We included ARIC participants who had an adjudicated 
diagnosis of hospitalized acute decompensated (ADHF) or chronic HF in 2006–2009 and 
documentation of discharge medications from chart abstraction.
Methods
The ARIC study is an on-going predominantly biracial cohort of 15,792 men and women 
from 4 US communities (Forsyth County, North Carolina; Minneapolis, Minnesota; Jackson, 
Mississippi; and Washington County, Maryland) and followed since 1987–89.12 The ARIC 
study began detailed abstraction of hospital discharge records for cohort members 
hospitalized with HF in 2005, as previously described.13 In brief, inclusion criteria for 
detailed abstraction included an International Classification of Diseases-Ninth Revision-
Clinical Modification (ICD-9-CM) discharge diagnosis code for HF or a related condition or 
symptom (398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 
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415.0, 416.9, 425.4, 428.x, 518.4, 786.0x). Discharge diagnosis codes could be in any 
position for inclusion. Study participants’ hospitalization records were reviewed for 
evidence of signs and symptoms of HF, including new onset or worsening shortness of 
breath, peripheral edema, paroxysmal dyspnea, orthopnea, and hypoxia. In the presence of 
such evidence, a detailed abstraction of the medical record was completed. HF was 
classified as definite or possible ADHF or as chronic stable heart failure by independent 
physician reviewers. The ability to distinguish between ADHF and chronic stable HF is a 
strength of the ARIC study.
Data on participant demographics and hospitalizations came from the ARIC study. 
Validated hospitalizations for ADHF or chronic stable HF were identified and merged with 
Medicare Provider Analysis and Review (MedPAR) inpatient stay records, Medicare 
hospice claims, and Medicare Part D claims using unique ARIC study participant identifiers 
and information concerning dates of service. The MedPAR records were used to obtain 
information on days in skilled nursing facility and all-cause hospital admissions that were 
not abstracted. For this analysis, claims for Medicare Part D prescriptions were identified 
using National Drug Codes and examined by medication class. Since the ARIC study 
collects information on all hospitalizations through active surveillance, we were able to 
include Medicare Advantage enrollees as well as fee-for-service enrollees. To ensure 
capture of all Part D medication fills (e.g., 90 day fills), ARIC study participants were 
included in this retrospective analysis if they were enrolled in Medicare Part D at the time of 
discharge and for at least 3 months prior to hospitalization. Only the first HF hospitalization 
observed between April 2006 and December 2009 was used for each participant in order to 
depict adherence over a 12 month period and enable comparability of assessment to other 
studies looking at annual rates of adherence. Participant characteristics including 
comorbidities, history of HF hospitalization, blood pressure, heart rate, laboratory values, 
and discharge medications were abstracted from the chart. Assessments of left ventricular 
function and left ventricular ejection fraction (LVEF) were documented in the current or 
previously available medical records or in reports of cardiac imaging (echocardiography, 
cardiac catheterization, and nuclear or other cardiac imaging) available to ARIC.
The study population included 834 ARIC cohort participants who had a hospitalization for 
ADHF or chronic stable HF from April 2006 through December 2009. We excluded 5 
participants who were Veterans and had no Part D claims filed for the three medications at 
any point during the study period. A total of 426 participants had documentation regarding 
medications prescribed at discharge, as well as Part D enrollment for at least 3 months prior 
to discharge. We excluded 24 participants who were not discharged on any of the three 
classes of medications. The final study sample was 402.
Prescriptions at discharge for ACEI/ARB, BB, or diuretic therapy were documented by chart 
abstraction. Proportion of ambulatory days covered (PADC) was determined using fill date 
and days supplied and was calculated as proportion of days the drug was available during 
the study period divided by the number of days the patient was not in a hospital, skilled 
nursing facility, or hospice. To account for switches within a class or changes in dose, 
PADC was not calculated in excess of 1 for any time period. The PADC was determined for 
up to twelve 30-day periods after hospital discharge for each medication; the 30-day periods 
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are subsequently referred to as “months.” Medication adherence was defined as ≥80% 
PADC over the specified time period. Observations were censored by death or end of study 
period (12/31/2009); observations were only included in the calculation of adherence each 
month if the person had at least some days in an ambulatory setting (i.e., days not in a 
hospital, skilled nursing facility, or on the Medicare hospice benefit). Bivariate associations 
of medication adherence class over the first 3 months following discharge were assessed 
using chi-square tests (for dichotomous participant characteristics) or t-tests (continuous 
measures) for each drug. We examined the following participant characteristics from the 
hospitalization in relation to adherence: demographics, comorbidities, history of HF 
hospitalization, ADHF vs. chronic HF, heart failure type, LVEF, assessment of LVEF 
during hospitalization, blood pressure, heart rate, serum sodium, serum creatinine, length of 
stay, and adherence to the other two medication classes.
Results
Overall, we studied 402 ARIC cohort participants who were hospitalized for ADHF or 
chronic stable HF from April 2006 through December 2009, had medications documented at 
discharge and were enrolled in Part D for at least 3 months prior to discharge. Table 1 
provides characteristics of the sample of 402 participants with documentation of at least one 
of three medication classes at discharge. Participants were 75 ± 6 years of age, 30% were 
men, and 40% were black. The majority of participants, 70%, were hospitalized for ADHF. 
Documentation of LVEF was available for 83% of the 402 participants either by assessment 
during hospitalization, from information available in ARIC study records for a previous 
hospitalization, or imaging studies prior to the study period. Based on available 
documentation, 55% of participants with an assessment of left ventricular function had an 
LVEF <50%. Table 2 shows the proportion of the 402 participants prescribed various 
combinations of the following three medication classes. In total, 62% (n = 248) were 
discharged on ACEI/ARB, 76% (n = 305) on BB, and 80% (n = 321) on a diuretic. Only 
39% of participants were discharged on all three medication classes.
Medication adherence as measured by PADC was suboptimal (<80%) and declined after 
discharge for each medication class (Figures 1–3). Overall, adherence at 1, 3 and 12 months 
was: 70%, 61%, 53% for ACEI/ARB, 76%, 66%, 62% for BB, and 75%, 68%, 59% for 
diuretics. Participants with a medication fill during the first 30 day period after discharge, 
PADC >0, demonstrated a higher adherence during subsequent periods. If the PADC was >0 
in the first 30 day period, adherence at 1, 3 and 12 months was: 86%, 71%, 60% for ACEI/
ARB, 88%, 73%, 63% for BB, and 86%, 75%, 64% for diuretics. Adherence declined the 
most over the first 2–4 months after hospital discharge for all three medication classes. For 
participants who did not have a medication fill within 30 days of discharge (PADC = 0 in 
the first period), medication adherence was poor (i.e., <80% PADC). Adherence to 
ACEI/ARB and diuretics never exceeded 40% over the study period. Adherence to BB 
improved over time but remained low. We also calculated the proportion of participants with 
non-persistence, defined as those who did not have a medication fill for ≥90 consecutive 
days, and those with discontinuation defined as non-persistence with no subsequent 
medication claims. At least 1 episode of non-persistence was observed in 25% of 
participants prescribed an ACEI/ARB, and 16% for both BB and diuretics. Discontinuation 
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was documented in 21%, 12%, and 11% of participants prescribed an ACEI/ARB, BB, and 
diuretic, respectively.
We explored bivariate associations between adherence to individual drug classes over the 
first 3 months after hospitalization and participant characteristics listed in Table 1. We found 
a limited number of associations that were significant at p ≤0.05. (Table 3) Blacks in 
Jackson and Forsyth had lower adherence than whites for ACEI/ARB and BB. Relative to 
participants in other sites, participants in Washington County, MD were more adherent to 
ACEI/ARB and BB. Participants with lung disease had worse adherence to BB. Higher 
serum creatinine was associated with worse adherence to ACEI/ARB therapy. Adherence to 
any single drug class was positively associated with the likelihood of being adherent to the 
other discharge medication classes. Age, gender, other comorbidities, hospitalization due to 
ADHF compared to chronic HF, assessment of LVEF during hospitalization, any 
documentation of LVEF, LVEF <50% or ≤40%, heart rate, or length of stay were not 
associated with medication adherence.
Discussion
To our knowledge, this is the first study to investigate monthly medication adherence to 
ACE-I/ARB, BB, and diuretics immediately after hospitalization in patients with validated 
HF using Medicare Part D data with chart documentation of discharge medications. These 
ARIC participants should not have had a contraindication to ACE-I/ARB or BB therapy 
since they were prescribed at discharge. We found that adherence to all 3 medication classes 
was not optimal and declined over time, with the largest decrease occurring during the first 
2–4 months after hospital discharge. Approximately 60% of the sample was adherent from 
the fourth month onward.
In the prior study most similar to ours, Butler et al. reported only ACE-I/ARB use measured 
by fill frequency in Medicaid patients hospitalized with HF during 1998–2001.9 In our more 
contemporary older cohort, we found a higher initial adherence rate for ACEI/ARB. 
However, adherence declined to similarly low levels by month 4. We saw a similar pattern 
for BB. Adherence to diuretics, not previously reported, was characterized by a less steep 
decline over the first few months post discharge which may reflect the immediate symptom 
relief with this therapy.
Other prior US studies have reported low (35–61%) long-term utilization, generally over a 
1-year period.1, 3, 6, 8 Medication adherence was based on filled prescriptions which may 
overestimate adherence. A few studies have utilized Part D data but have not reported 
adherence immediately post discharge. Part D implementation has resulted in modest 
improvements in medications adherence as reported by Donohue et al.7 Zhang et al. reported 
52% of patients had good adherence for HF medications up to one year in a 5% sample of 
Medicare fee for-service beneficiaries with 1 inpatient or 2 outpatient claims for HF during 
2007–2009.5 Adherence to individual medications was not reported. In our study, short-term 
adherence rates for ARIC participants with PADC ≥80% in the first month were 
substantially higher but declined by 22–26% to similar rates by the end of the study, 63%, 
60%, and 64% for BB, ACE-I, and diuretics, respectively. Our data highlight the need to 
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identify the predictors for the early decline in adherence after hospitalization in order to 
develop appropriate interventions. Our data suggest that focused interventions to improve 
adherence should extend over several months post-discharge to maintain the higher 30 day 
adherence rates.
A recent literature review by Oosterom-Calo concluded that predictors of medication 
adherence were inconsistent for age, gender, ethnicity, social support, functional status, 
depression, patient perceived barriers, and number of comorbidities.14 Single studies found 
that coronary artery disease, diabetes, hyperlipidemia, and asthma/chronic obstructive lung 
disease were associated with increased adherence, while renal disease was associated with 
lower adherence. The only consistent predictor of good adherence was history of 
hospitalization or a nursing home stay. In our study, worse renal function and previous HF 
hospitalization were associated with poor adherence to ACEI/ARB. Lung disease was 
associated with poor adherence to BB. Subsequent studies have reported geographic and 
ethnic variation in medication adherence.4, 5 Although we observed differences in patterns 
of medication adherence to ACEI/ARC and BB by ARIC geographic site, we were not able 
to separate out the residual confounding effects of race and unmeasured area-specific 
healthcare systems characteristics. We examined several variables not commonly reported in 
previous studies. In our study, post discharge adherence does not appear to be different 
between participants admitted with an ADHF compared to those admitted with chronic 
stable HF. Ejection fraction was not associated with adherence measured either as a 
continuous variable or as a categorical variable based on a priori-defined cut points: <50% 
and <40%. Adherence to any single drug class was highly correlated with being adherent to 
other medication classes. This finding suggests that medication non-adherence is not solely 
due to adverse effects or discontinuation. Our findings confirm the complexity of predictors 
of medication adherence and suggest that adherence may depend not only on the specific 
medication but also the patient population.
This analysis is subject to several limitations. The results may not be generalizable to 
patients who are not on Medicare Part D, though we were able to include both Medicare fee-
for-service and Medicare Advantage. Our measure of adherence could be too low if claims 
are missing due to participants being in the donut hole or receiving medications through a 
generic drug plan, or veteran drug benefits. However, many pharmacies continue to submit 
claims to Medicare even when the beneficiary is responsible for the full payment.15–17 A 
study of medication adherence in patients with depression and HF showed only a modest 
reduction in adherence for persons in the donut hole,.15 We excluded veterans who never 
filed a medication claim. Medicare Part D claims were never filed for 6–9% of our 
participants (23/248 for ACEI/ARB, 18/305 for BB and 21/321 for diuretics). However, 
approximately 60% of these participants had claims filed for other medications, consistent 
with non-adherence rather than missing claims. Also, medication adherence still declined 
between 22–26% for all 3 medication classes over the study period among participants with 
an initial fill. ARIC does not collect follow up visit data post discharge so we did not have 
data on medication discontinuation by providers e.g. due to worsening renal function. 
Strengths of our study include: examining adherence in patients with known discharge 
medications, not just users; identifying patterns of adherence over time; the adjudication of 
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hospitalizations with differentiation between acute exacerbation vs chronic stable HF; and 
clinical data not available through claims e.g. LVEF, laboratory values.
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Proportion of patients discharged on ACEI/ARB with PADC ≥80% by 30 day periods after 
hospital discharge
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Proportion of patients discharged on beta blockers with PADC ≥80% by 30 day periods 
hospital discharge
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Proportion of patients discharged on diuretics with PADC ≥80% by 30 day periods after 
hospital discharge
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Table 1
Sample Demographic and Clinical Characteristics (n=402)
Characteristic Mean (±SD) or %
Age, years 75.4 ± 5.6
Male 30%
ARIC geographic region and race Washington County white 18%
Forsyth County white 21%












Previous HF hospitalization 42%
Acute decompensated HF 70%
Systolic blood pressure (mmHg) 145 ± 33
Heart rate (bpm) 87 ± 23
Serum sodium (mmol/L) 136 ± 4.4
Serum blood urea nitrogen (mg/dl) 38 ± 23
Serum creatinine (mg/dl) 2 ± 1.6
Glomerular filtration rate (ml/min/1.73m2) 42 ± 21
LV assessment during hospitalization 51%
LVEF 43% ± 17.4
LVEF ≤ 40% 40%
LVEF < 50% 55%
Hospital length of stay (days) 7.6 ± 15.5
HF = heart failure; LVEF = left ventricular ejection fraction.
LVEF was missing for 17% of cases.













Sueta et al. Page 13
Table 2
Drug Prescriptions at Hospital Discharge
Medication Classes (n=402)
ACEI/ARB + BB + Diuretic 155 (39%)
BB + Diuretic 76 (19%)
Diuretic 46 (11%)
ACEI/ARB + Diuretic 44 (11%)
ACEI/ARB + BB 42 (10%)
BB 32 (8%)
ACEI/ARB 27 (2%)
ACEI/ARB = angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BB = beta blocker.
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